OBJECTIVE: Peroxisome proliferator-activated receptor (PPAR) alpha/gamma dual agonists have the potential to be used as therapeutic agents for the treatment of type 2 diabetes. This study evaluated the function of macelignan, a natural compound isolated from Myristica fragrans, as a dual agonist for PPARalpha/gamma and investigated its antidiabetes effects in animal models. RESEARCH DESIGN AND METHODS: GAL4/PPAR chimera transactivation was performed and the expression of PPARalpha/gamma target genes was monitored to examine the ability of macelignan to activate PPARalpha/gamma. Additionally, macelignan was administrated to obese diabetic (db/db) mice to investigate antidiabetes effects and elucidate its molecular mechanisms. RESULTS: Macelignan reduced serum glucose, insulin, triglycerides, free fatty acid levels, and triglycerides levels in the skeletal muscle and liver of db/db mice. Furthermore, macelignan significantly improved glucose and insulin tolerance in these mice, and without altering food intake, their body weights were slightly reduced while weights of troglitazone-treated mice increased. Macelignan increased adiponectin expression in adipose tissue and serum, whereas the expression and serum levels of tumor necrosis factor-alpha and interleukin-6 decreased. Macelignan downregulated inflammatory gene expression in the liver and increased AMP-activated protein kinase activation in the skeletal muscle of db/db mice. Strikingly, macelignan reduced endoplasmic reticulum (ER) stress and c-Jun NH(2)-terminal kinase activation in the liver and adipose tissue of db/db mice and subsequently increased insulin signaling. CONCLUSIONS: Macelignan enhanced insulin sensitivity and improved lipid metabolic disorders by activating PPARalpha/gamma and attenuating ER stress, suggesting that it has potential as an antidiabetes agent for the treatment of type 2 diabetes.
OBJECTIVE:Peroxisome proliferator-activated receptor (PPAR) alpha/gamma dual agonists have the potential to be used as therapeutic agents for the treatment of type 2 diabetes. This study evaluated the function of macelignan, a natural compound isolated from Myristica fragrans, as a dual agonist for PPARalpha/gamma and investigated its antidiabetes effects in animal models. RESEARCH DESIGN AND METHODS: GAL4/PPAR chimera transactivation was performed and the expression of PPARalpha/gamma target genes was monitored to examine the ability of macelignan to activate PPARalpha/gamma. Additionally, macelignan was administrated to obese diabetic (db/db) mice to investigate antidiabetes effects and elucidate its molecular mechanisms. RESULTS:Macelignan reduced serum glucose, insulin, triglycerides, free fatty acid levels, and triglycerides levels in the skeletal muscle and liver of db/db mice. Furthermore, macelignan significantly improved glucose and insulin tolerance in these mice, and without altering food intake, their body weights were slightly reduced while weights of troglitazone-treated mice increased. Macelignan increased adiponectin expression in adipose tissue and serum, whereas the expression and serum levels of tumor necrosis factor-alpha and interleukin-6 decreased. Macelignan downregulated inflammatory gene expression in the liver and increased AMP-activated protein kinase activation in the skeletal muscle of db/db mice. Strikingly, macelignan reduced endoplasmic reticulum (ER) stress and c-Jun NH(2)-terminal kinase activation in the liver and adipose tissue of db/db mice and subsequently increased insulin signaling. CONCLUSIONS:Macelignan enhanced insulin sensitivity and improved lipidmetabolic disorders by activating PPARalpha/gamma and attenuating ER stress, suggesting that it has potential as an antidiabetes agent for the treatment of type 2 diabetes.
Authors: Giorgio Biasiotto; Marialetizia Penza; Isabella Zanella; Moris Cadei; Luigi Caimi; Cristina Rossini; Annika I Smeds; Diego Di Lorenzo Journal: Eur J Nutr Date: 2014-02-25 Impact factor: 5.614
Authors: Neda Rasouli; Philip A Kern; Steven C Elbein; Neeraj K Sharma; Swapan K Das Journal: Pharmacogenet Genomics Date: 2012-07 Impact factor: 2.089
Authors: Joel R Garbow; Jason M Doherty; Rebecca C Schugar; Sarah Travers; Mary L Weber; Anna E Wentz; Nkiruka Ezenwajiaku; David G Cotter; Elizabeth M Brunt; Peter A Crawford Journal: Am J Physiol Gastrointest Liver Physiol Date: 2011-03-31 Impact factor: 4.052
Authors: Adeel Rehman; Keith C Hemmert; Atsuo Ochi; Mohsin Jamal; Justin R Henning; Rocky Barilla; Juan P Quesada; Constantinos P Zambirinis; Kerry Tang; Melvin Ego-Osuala; Raghavendra S Rao; Stephanie Greco; Michael Deutsch; Suchithra Narayan; H Leon Pachter; Christopher S Graffeo; Devrim Acehan; George Miller Journal: J Immunol Date: 2013-03-27 Impact factor: 5.422
Authors: Kasi C McPherson; Lateia Taylor; Ashley C Johnson; Sean P Didion; Aron M Geurts; Michael R Garrett; Jan M Williams Journal: Am J Physiol Renal Physiol Date: 2016-07-27